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lecular map of their impact on GvHD, we performed tran-
scriptomic analysis, on CD3+/CD20- T cells that were puriﬁed
on day +14.
The synergistic impact of combined belatacept +sirolimus
was evidenced through all analyses techniques: Thus, GvHD-
free survival with belatacept + sirolimus was prolonged
compared to all other groups (MST belatacept + sirolimus ¼
33d, p< 0.02) compared toMST for untreated controls (7.5d),
belatacept monotherapy (9d, p < 0.03) and sirolimus mon-
otherapy (12d, p <0.05), with GvHD clinical scores as well as
canonical ﬂow cytometric signs of CD8+ T cell activation and
excessive cytotoxicity mirroring the clinical survival.
Comparing the expression proﬁle of T cells during acute
GvHD allowed examination of treatment synergy at an un-
precedented level of molecular detail. Unsupervised analysis
revealed clustering of principal components from belatacept
+ sirolimus to be strikingly similar to a large comparative
healthy control cohort (n¼28), underscoring the high
degree of early control of alloreactivity with this regimen.
Moreover, the comparison of differentially expressed genes
from animals receiving belatacept + sirolimus revealed sig-
niﬁcant divergence from monotherapy with either belata-
cept or sirolimus, again underscoring the profound control of
allo-activation that was observed with belatacept + siroli-
mus. Those genes for which expression was signiﬁcantly
normalized showed pathway enrichment prominently in
T cell effector function (prominently including granzyme
signaling), cytokine networks (prominently IL2, IL12 and IL-
18), as well as in proliferation and cell cycle pathways.
These data reveal a treatment synergy between T cell
costimulation blockade with CTLA-4-Ig and mTOR inhibition
and suggest that this combination of therapies will be useful
for acute GvHD immunoprophylaxis in humans.479
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Disease relapse is still a major cause of treatment failure after
allogeneic hematopoietic cell transplant (HCT). Although
outcomes are still poor, donor cellular infusions (DCI) and
second HCT are still the more commonly used treatment
strategies to treat relapse after transplant. Little is known,
however, regarding the comparable efﬁcacy of either strat-
egy. We thus undertook this retrospective review of patients
relapsing after allogeneic HCT.We identiﬁed 73 patients who
had relapsed after their ﬁrst allogeneic transplant and
received either a DCI (n¼38) or second HCT (n¼35), as
deﬁned by CIBMTR criteria. Patients in the two groups were
matched according to basic demographic information
including gender, race, performance status, comorbidity in-
dex, transplant type, donor source, and diagnosis, which
included both myeloid and lymphoid hematologic malig-
nancies. Patients who underwent a DCI were slightly older,
median 51 years (18-67) compared to thosewho received 2ndtransplant, median 46 years (range 16-66), p¼0.06; and had
a worst grade of GVHD after their ﬁrst transplant, grade 2,
n¼14, 37% for DCI, and n¼5, 14% for 2nd transplant, p¼0.028.
Most patients who underwent DCI received cytoreductive
chemotherapy prior to infusion, n¼24/36 (67%); likewise
patients who underwent 2nd HCT also received some form of
therapy prior to their second procedure, n¼17/34, (50%).
Patients who underwent 2nd transplant had a higher inci-
dence of acute grade 2-4 GVHD, 43% compared to 13% for DCI
at 6 months, p¼0.032, with no signiﬁcant differences in se-
vere grade 3-4 GVHD, p¼0.15. There were also no signiﬁcant
differences in chronic GVHD, 35% for 2nd HCT compared to
26% for DCI at 3 years, p¼0.58. Relapse mortality was
signiﬁcantly higher in recipients of DCI compared to 2nd
transplant, 56% compared to 33%, p¼0.011, respectively;
whereas non-relapse mortality was signiﬁcantly higher in
2nd HCT, 56% compared to 32% in DCI recipients, p¼0.024.
Overall survival at 5 years was similar in both groups, 10% in
2nd HCT recipients versus 12% in DCI recipients, p¼0.44. In
multivariable analysis, months from 1st HCT HR 0.76 per 6
month increase (95% CI 0.62-0.93, p¼0.007) and DCI (HR
2.06, 95% CI 1.02-4.15, p¼0.043) were risk factors for relapse
mortality. Conversely, 2nd HCT was associated with higher
non-relapse mortality compared to DCI (HR 2.38, 95% CI 1.15-
5, p¼0.019). Months from initial transplant (HR 0.92, 95% CI
0.85-0.99, p¼0.028), and blast count prior to second proce-
dure (HR 1.12 per 10% increase, 95% CI 1.02-1.23, p¼0.017)
were the only risk factors for all-cause mortality.
In summary, we found no differences in overall survival
between DCI and 2nd HCT. DCI was associated with higher
relapse mortality, whereas 2nd HCT was associated with
higher non-relapse mortality. Both modalities have poor
survival rates and improved therapeutic options are needed
for relapse after HCT.480
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Aim: The presence of activated CMRF-44+ (Lau, 2007, Trans-
plantation, 83:839) and CCR5+ CD16+ (Shahin, 2013, Trans-
plantation, 96:753) dendritic cells (DC) predicted for acute
graft versus host disease (GVHD) after clinical allogeneic
hematopoietic cell transplantation (alloHCT). We are devel-
oping anti-DC monoclonal antibodies (mAb) as novel
immunosuppressive agents and have shown that polyclonal
